Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Eli Lilly and : Says Taltz Met Endpoints in Axial Spondyloarthritis Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/12/2019 | 08:14am EST

By Michael Dabaie

Eli Lilly and Co. (LLY) said Taltz met the primary and all major secondary endpoints in the COAST-X placebo-controlled Phase 3 study in non-radiographic axial spondyloarthritis.

In the study, Taltz improved the signs and symptoms of non-radiographic axSpA as measured by ASAS40, as well as reduced inflammation on MRI, the company said.

Axial spondyloarthritis is a chronic inflammatory disease affecting predominantly the sacroiliac joints and the spine skeleton and is estimated to affect 4.5 million adults worldwide.

A total of 303 adult patients with active nr-axSpA were randomized to receive Taltz 80 mg subcutaneously every four weeks or every two weeks, or placebo. At week 16, 35% of patients treated every four weeks and 40% of patients treated every two weeks achieved ASAS40 response, compared with 19% with placebo. At week 52, 30% treated every four weeks and 31% treated every two weeks achieved ASAS40 response, compared with 13% with placebo.

Write to Michael Dabaie at michael.dabaie@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND COMPANY
07:49aBNP Paribas AM Launches World Climate Carbon Offset Plan Fund
DJ
01/17Health Executives Brace for Change In Regulation and Competition -- WSJ
DJ
01/16DERMIRA : Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - C..
RE
01/16ELI LILLY AND : Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 ..
PR
01/16Health Executives Gear Up for Change at J.P. Morgan Conference
DJ
01/16ELI LILLY AND : Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase..
AQ
01/15ELI LILLY AND : Lilly expands insulin affordability options with lower-priced ve..
AQ
01/14ELI LILLY AND COMPANY : - Tyvyt Combined with ALIMTA and Platinum Met Predefined..
AQ
01/14ELI LILLY AND : Lilly expands insulin affordability options with lower-priced ve..
PR
01/13ELI LILLY AND : Lilly Announces Agreement to Acquire Dermira
AQ
More news
Financials (USD)
Sales 2019 22 139 M
EBIT 2019 6 009 M
Net income 2019 8 052 M
Debt 2019 12 303 M
Yield 2019 1,82%
P/E ratio 2019 16,4x
P/E ratio 2020 22,8x
EV / Sales2019 6,61x
EV / Sales2020 6,11x
Capitalization 134 B
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 139,64  $
Last Close Price 139,58  $
Spread / Highest target 18,2%
Spread / Average Target 0,05%
Spread / Lowest Target -19,0%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Myles Oneill Senior VP & President-Manufacturing Operations
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information Officer & SVP-IT
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY6.20%134 015
JOHNSON & JOHNSON2.26%392 596
ROCHE HOLDING AG4.44%289 160
MERCK AND COMPANY0.02%231 608
PFIZER3.39%224 187
NOVARTIS0.96%217 045